8 results
To describe the pharmacokinetic (PK) profile and effectiveness of sarilumab in patients with sJIA in order to identifythe dose and regimen for continued development in this population.
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in patients of all ages with mild (FVIII level between > 5% and < 40%) or moderate hemophilia A (FVIII level between >= 1% and…
The Primary objective is: 1) To investigate clinical effectiveness of the glutamatergic compound memantine in paediatric patients with: - Obessive-Compulsive Disorder (OCD) GOAT-1 - Autism Spectrum Disorder (ASD) GOAT-2 with respect to symptoms of…
To evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.The primary efficacy endpoint of this study is * Overall survivalThe secondary efficacy endpoints of this…
The aim of the study is to evaluate the efficacy and safety of three IV treatment regimens of sifalimumab in adult subjects with chronic, moderately-to-severely active SLE with an inadequate response to SOC SLE (Standard Of Care treatment for SLE).…
1. To investigate the safety and tolerability of single oral doses of NS11821 in healthy male subjects and estimate a maximum tolerated dose.2. To investigate the pharmacokinetics (PK) of single ascending oral doses of NS11821.
Study MO41787 will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 mg/kg Q2W for a period of 52 weeks in previously untreated patients (PUPs) and minimally treated patients (MTPs) at study…
Primary objectiveTo determine whether individualized pharmacokinetic (PK)-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the - proportion of patients without treated bleeds (6 months before and after intervention…